Kiadis Pharma, Amsterdam, The Netherlands, announced the FDA has approved the company's investigational new drug application (IND) to allow the start of a clinical phase III study for its product Reviroc in the US. Reviroc is under development for the elimination of cancer cells from an autologous graft in bone marrow transplantation for end-stage blood cancer patients.

The company says the approval followed the successful end of a phase II trial. As part of ...